Genomics BioSci & Tech. Co.,Ltd.
4195.TWO
Taipei Exchange29.45
TWD
- -
- -
Genomics BioSci & Tech. Co.,Ltd.
4195.TWO
(Taipei Exchange)
Recent
price
29.45
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Genomics BioSci & Tech. Co., Ltd. operates as a leading biotechnology company specializing in genomics and genetic analysis, headquartered in New Taipei City, Taiwan, and founded in 2001. The company offers comprehensive sequencing services, including first, second, and third-generation sequencing platforms; regular DNA sequencing; complex sequence and TAF certified sequencing; RNA and gene expression sequencing; microbial sequencing; and genomic sequencing services covering genome-level, targeted, gene regulation, and metagenomics. Its synthesis services comprise oligonucleotide, probe, RNA, gene, and peptide synthesis. Genomics also provides proteomic services, including Olink proteomic assays for protein biomarker screening, and extensive testing and analytical services such as sample preparation, gene expression analysis, genotyping, DNA methylation analysis, and microbial identification. Additionally, the company has a contract development and manufacturing segment (CDMO) supporting vaccine adjuvant and active pharmaceutical ingredient (API) development, from pre-clinical to clinical phases, catering to the vaccine adjuvant, cellular, and gene therapy industries. Recent strategic developments include signing an exclusive agency contract with Thermo Fisher for the Taiwan region, acquiring a 16% stake in Wyzer Biosciences to enter the U.S. market, launching its first nucleic acid adjuvant product with planned GMP plant inspection, and demonstrating milestone outcomes of its PIC/S GMP nucleic acid and peptide pilot plant at BIO Asia-Taiwan. The company has expanded its CDMO offerings by transforming nucleic acid synthesis services from academic research provision to raw material supply for high-grade detection probe kits and nucleic medications, forming strategic alliances to develop new products, broadening clinical applications, and venturing into precision gene therapy and cancer therapy as integrated service solutions. Genomics BioSci & Tech serves a diverse customer base including research institutions, biotechnology companies, and medical centers, predominantly operating in Taiwan with growing international presence through partnerships and equity investments. The company maintains advanced proprietary production lines and strong bioinformatics capabilities to support its full-service pipeline from production to data analysis.